Compare Neurocrine Biosciences Inc (NBIX) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Seagate Technology Holdings PLC — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Seagate Technology Holdings PLC trades at $879.98 (market cap $201.45B). The key difference: Seagate Technology Holdings PLC is far larger — about 12.8× Neurocrine Biosciences Inc's market cap, and Seagate Technology Holdings PLC pays a 0.33% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | STX | |
|---|---|---|
Market Cap | $15.77B | $201.45B |
Sector | Health | Technology |
52-Week High | $185.50 | $1.09K |
52-Week Low | $123.10 | $193.04 |
Enterprise Value | $15.78B | $203.61B |
Dividend Yield | — | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
STX trades at $904.38, up 6.49% in 24 hours, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a net income margin of 26.11% and high ROE of 371.53%, though valuation ratios like P/E of 65.06 appear elevated. Recent news highlights AI-driven storage demand and HAMR technology advancements fueling growth, with revenue projected to rise to $12.2B in 2026.
Outlook is positive due to AI infrastructure demand and earnings momentum, but risks include high debt levels and valuation concerns. Analysts are bullish with a consensus price target of $1,130, suggesting upside potential, though investors should monitor execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
